Make a Living ClubMake a Living Club
  • Home
  • News
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • More
    • Economy
    • Politics
    • Real Estate
Trending Now

Trulieve Cannabis: Cash-Generative Platform With Schedule III Optionality (OTCMKTS:TCNNF)

December 18, 2025

Maui Land & Pineapple: Rate Cuts Should Help Real Estate Plays (MLP)

December 16, 2025

HAP: An Option To Consider If Inflation And Commodities Rise In 2026 (NYSEARCA:HAP)

December 15, 2025

Brussels imposes sanctions on oil trader Murtaza Lakhani over Russia allegations

December 15, 2025

Invesco Charter Fund Q3 2025 Portfolio Positioning And Performance Highlights

December 14, 2025

At least 11 people killed in terror attack on Jewish festival at Sydney’s Bondi Beach

December 14, 2025
Facebook Twitter Instagram
  • Privacy
  • Terms
  • Press
  • Advertise
  • Contact
Facebook Twitter Instagram
Make a Living ClubMake a Living Club
  • Home
  • News
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • More
    • Economy
    • Politics
    • Real Estate
Sign Up for News & Alerts
Make a Living ClubMake a Living Club
Home » Explainer-What you need to know about RSV and the new vaccines
Stocks

Explainer-What you need to know about RSV and the new vaccines

Press RoomBy Press RoomSeptember 24, 2023
Facebook Twitter Pinterest LinkedIn WhatsApp Email
2/2

© Reuters. FILE PHOTO: A company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

2/2

By Michael Erman

(Reuters) -The U.S. Centers for Disease Control and Prevention (CDC) on Friday recommended Pfizer (NYSE:)’s respiratory syncytial virus (RSV) vaccine for women in the middle of the third trimester of pregnancy to protect their babies from severe illness.

That Pfizer shot and one developed by GSK in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness. In August, Pfizer’s vaccine also won approval for the maternal use. Here’s what you need to know.

What is RSV?

RSV is a usually seasonal respiratory virus that generally causes mild, cold-like symptoms. Still, infants and older adults have a higher risk of developing severe RSV.

RSV leads to 58,000 to 80,000 hospitalizations among children under age 5, and 60,000 to 160,000 hospitalizations among adults age 65 and older each year, according to the CDC. It causes around 14,000 deaths in adults aged 65 and older in the U.S. annually, according to government estimates.

Who should get the vaccines?

The U.S. CDC has recommended that adults aged 60 or older may get the shot after discussions with a healthcare provider about whether RSV vaccination is right for them. The agency stopped short of saying all adults over the age of 60 should receive it this year.

Outside advisers to the CDC suggested the narrower recommendation in June after expressing concern that there was not sufficient data on how effective the vaccines are in people over age 75 and in other high-risk groups.

CDC Director Dr. Mandy Cohen formally recommended use of the vaccine in expecting mothers to protect infants up to age 6 months after the agency’s Advisory Committee on Immunization Practices voted 11-1 in its favor. The panel recommended use of the shot in women 32 weeks to 36 weeks into their pregnancy from September to January, in order to protect babies born in peak RSV season.

How often do I need to get the vaccine to stay protected?

Early data suggests that the RSV shots are protective for at least two years, but it is not yet clear how often older adults will need to be revaccinated. CDC advisers will consider the frequency of revaccination when more data becomes available.

What else is available to protect infants from RSV?

In July, the FDA also approved Beyfortus, a long-acting antibody therapy from Sanofi (NASDAQ:) and partner AstraZeneca (NASDAQ:), to prevent RSV in children up to 24 months of age.

Previously, Swedish Orphan Biovitrum’s Synagis was the only approved preventive therapy in the U.S. for high-risk infants. Synagis is given as monthly injections, while Beyfortus can be given annually.

Are RSV cases on the rise?

Yes, although not alarmingly so. Detection of the virus in testing has increased significantly over the last month to around the same levels as this spring, according to CDC data. Still, that is a fraction of the positive tests recorded at the same time a year ago, when RSV cases were surging around the country and hospitals were running out of pediatric beds.

Can I get the RSV shot alongside my COVID and flu shots?

Yes, current CDC guidelines allow for all three vaccines to be administered simultaneously, even though they have not been tested together.

“If it’s now or never again, it’s best to get all the vaccines you’re eligible for to get the protection against as many diseases as possible,” said Dr. Jeffrey Duchin, a member of the board of directors for the Infectious Diseases Society of America. “If you’ve got the luxury of returning for more than one visit, you can choose to space them out.”

Will my insurance cover it?

Adults who are insured under the U.S. Medicare program for people aged 65 and older or disabled are covered for the vaccine. Many private insurance plans, including large insurers like CVS Health (NYSE:)’s Aetna, Humana (NYSE:) and Elevance, which owns Blue Cross Blue Shield insurers including Anthem, also say they are covering the shot for adults 60 and older who are not yet eligible for Medicare. Typically you do not need a prescription.

Keep up with the latest medical breakthroughs and healthcare trends with our newsletter Reuters Health Rounds. Sign up here.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Wall Street eyes Microsoft’s AI bets and cloud growth By Investing.com

Stocks March 26, 2024

Robinhood woos wealthier clients from bigger brokerages- WSJ

Stocks March 25, 2024

Elon Musk says oil and gas should not be demonised

Stocks March 25, 2024

Pro Research: Wall Street dives into Alphabet’s potential and pitfalls

Stocks December 25, 2023

Pro Research: Wall Street eyes on First Solar’s bright future

Stocks December 24, 2023

US court orders new FTC review of Illumina’s Grail deal

Stocks December 23, 2023
Add A Comment

Leave A Reply Cancel Reply

Latest News

Maui Land & Pineapple: Rate Cuts Should Help Real Estate Plays (MLP)

December 16, 2025

HAP: An Option To Consider If Inflation And Commodities Rise In 2026 (NYSEARCA:HAP)

December 15, 2025

Brussels imposes sanctions on oil trader Murtaza Lakhani over Russia allegations

December 15, 2025

Invesco Charter Fund Q3 2025 Portfolio Positioning And Performance Highlights

December 14, 2025

At least 11 people killed in terror attack on Jewish festival at Sydney’s Bondi Beach

December 14, 2025
Trending Now

Wall Street Roundup: Market Reacts To Earnings

December 12, 2025

Bear Market? Prepare Now With These 5 Best Stocks

December 11, 2025

TWFG: A Growing Insurance ‘Middle Man’ (NASDAQ:TWFG)

December 10, 2025

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Make a Living is your one-stop news website for the latest personal finance, investing and markets news and updates, follow us now to get the news that matters to you.

We're social. Connect with us:

Facebook Twitter Instagram YouTube LinkedIn
Topics
  • Business
  • Economy
  • Finance
  • Investing
  • Markets
Quick Links
  • Cookie Policy
  • Advertise with us
  • Get in touch
  • Submit News
  • Newsletter

Subscribe to Updates

Get the latest finance, markets, and business news and updates directly to your inbox.

2025 © Make a Living Club. All Rights Reserved.
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.